Home › Arrhythmia › NCT05932602

AVEIR DR Coverage With Evidence Development (CED) Study

The AVEIR DR Coverage With Evidence Development (DRIVE) Study

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Medicare beneficiaries implanted with an Aveir DR leadless pacemaker on or after the study start date (i.e., the date of Aveir DR market approval) will be included in the study.

OR

Medicare beneficiaries implanted with a full system (e.g. lead and generator) dual-chamber transvenous pacemaker on or after the study start date

Exclusion Criteria:

None

About the study

The purpose of this coverage with evidence development (CED) study is to evaluate complications and long-term health outcomes of the dual chamber Aveir Leadless Pacemaker device (aka Aveir™ DR LP system).

What is being tested

• Aveir DR Leadless Pacemaker System (device)
• Dual Chamber Transvenous Pacemaker (device)

Sponsor: Abbott Medical Devices · Participants: 2,812 · Started: Oct 31, 2023

Contact the study team

• Nicole Harbert · Phone: 972-526-4841
• Stephanie Delgado · Phone: 818-493-3285

Official record on ClinicalTrials.gov — NCT05932602

Locations in the U.S.

Conditions

• Arrhythmia
• Bradycardia
• Atrioventricular Block

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.